Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Iterum Therapeutics, retaining the price target of $5.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Iterum Therapeutics’ strategic positioning and potential for growth. The company is on the verge of launching ORLYNVAH, a promising antibiotic for treating adult women with limited oral antibacterial options for urinary tract infections. This launch, supported by a partnership with EVERSANA for sales and commercial operations in the US, is expected to significantly enhance Iterum’s market presence.
Additionally, the drug’s broad-spectrum efficacy, covering over 95% of microbes associated with urinary tract infections, positions it as a competitive option in the market. The anticipated pricing aligns with existing treatment options, and the targeted demographic includes higher-risk populations, which could drive substantial demand. Iterum’s management has adeptly navigated regulatory challenges and market headwinds, setting the stage for a successful commercial rollout, which underpins McCarthy’s positive outlook on the stock.
McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Capricor Therapeutics, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -21.4% and a 26.81% success rate on recommended stocks.